What are the main ingredients of afatinib? Analysis of drug action mechanism

Afatinib is an oral, irreversible pan- ErbB receptor family inhibitor and belongs to the second generation EGFR-TKI anti-cancer drug. Its active ingredient is Afatinib dimaleate, which is a small molecule tyrosine kinase inhibitor that can effectively target the kinase activity of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) receptors, and has broad-spectrum anti-tumor potential.

Afatinib is unique in its "irreversible" binding mechanism, which means that it can covalently bind to the EGFR mutation site, making the inhibitory effect last longer. Compared with first-generation TKIs (such as gefitinib and erlotinib), afatinib has stronger affinity for some drug-resistant mutations, especially in patients with EGFR exon 19 deletion and L858R mutation, showing more durable tumor control ability.

The drug inhibits the growth, proliferation and migration of cancer cells by blocking the phosphorylation process in the EGFR signaling pathway and inhibiting the downstream PI3K/AKT and RAS/RAF/MEK pathways. In some non-small cell lung cancer related to HER2 mutations, afatinib also shows a certain targeting effect, providing a treatment option for patients with such rare mutations.

Although afatinib has limited effect on patients with KRAS mutations or EGFR T790M resistance mutations, its clinical value in EGFR-positive treatment-naïve patients is still significant. In addition, due to its irreversible binding mode, afatinib shows certain central nervous system penetration in some patients with brain metastases, although this still requires further clinical verification.

In summary, the main component of afatinibAfatinib dimaleate can precisely target and kill tumor cells by comprehensively inhibiting the activity of ErbB family receptors. Its pharmacological mechanism makes it play an important role in the treatment of EGFR mutant NSCLC and is a key member of the current targeted therapy strategy.

Reference materials:https://www.giotrif.com/